A Multicentre, Open-label, Three-arm Randomised Phase II Trial Assessing the Safety and Efficacy of the HSP90 Inhibitor Ganetespib in Combination With Carboplatin Followed by Maintenance Treatment With Niraparib Versus Ganetespib Plus Carboplatin Followed by Ganetespib and Niraparib Versus Carboplatin in Combination With Standard Chemotherapy Followed by Niraparib Maintenance Treatment in Platinum-sensitive Ovarian Cancer Patients

This study will be performed in women with platinum-sensitive, high-grade serous, high-grade endometrioid, undifferentiated epithelial ovarian cancer, carcinosarcoma, fallopian tube or primary peritoneal cancer (proven by central histo-pathological review).
A total of 120 subjects will be randomized (1:1:1) to three different treatment arms: (A) Standard arm (arm A): Carboplatin (AUC5 d1, q3w i.v.) in combination with Paclitaxel (175 mg/m² d1, q3w i.v.) or Carboplatin (AUC4 d1, q3w i.v.) in combination with Gemcitabine (1000 mg/m² d1, d8, q3w i.v.) followed by maintenance therapy with Niraparib (200/ 300 mg oral daily, q4w) // (B) First experimental arm (arm B): Ganetespib (150 mg/m2, d1, q3w) in combination with Carboplatin (AUC5 d1, q3w i.v.) followed by maintenance treatment with Niraparib (200/ 300 mg oral daily, q4w) // (C) Second experimental arm (arm C): Ganetespib (150 mg/m² d1, q3w i.v.) plus Carboplatin (AUC5 d1, q3w i.v.) followed by Ganetespib (100 mg/m² d1, d8, d15, d22, q4w i.v.) and Niraparib (200 mg oral daily, q4w).
Chemotherapy treatment will be given for 6 cycles, maintenance treatment with Ganetespib will be given for a maximum of 9 months or until disease progression, maintenance treatment with Niraparib can continue until disease progression.

Start Date30 Nov 2018

Sponsor / Collaborator

Universitaire Ziekenhuizen Leuven

NCT02637375

/ WithdrawnNot ApplicableIIT

A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer

Based on preclinical data implicating GR, AR, and JAK/STAT activation as potent mechanisms of breast cancer cell survival despite chemotherapy administration (i.e. chemotherapy resistance), the study will test a novel approach for improving chemotherapy effectiveness by adding Hsp90 inhibition to antagonize the anti-apoptotic signaling pathways that are initiated via GR, AR, and JAK/STAT activation.

Start Date01 May 2016

Sponsor / Collaborator

The University of Chicago

NCT02389751

/ CompletedPhase 1IIT

GUARDIAN-1 Trial: A Phase 1 Study of Ganetespib in Combination With Chemoradiation for Stage II-III Esophageal Carcinoma

This phase I trial studies the side effects and best dose of ganetespib when given together with paclitaxel, carboplatin, and radiation therapy in treating patients with stage II-III esophageal cancer. Ganetespib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving ganetespib in combination with paclitaxel, carboplatin, and radiation therapy may be a better treatment for patients with esophageal cancer.

Start Date10 Apr 2015

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

[+1]

100 Clinical Results associated with Ganetespib

100 Translational Medicine associated with Ganetespib

100 Patents (Medical) associated with Ganetespib

286

Literatures (Medical) associated with Ganetespib

01 Apr 2026·CELL DEATH AND DIFFERENTIATION

Mitochondria-transliterated ALDH1L1 functions as a feedback regulator of redox homeostasis in cancer cells to enhance the resistance to pro-oxidative therapy

Article

Author: Zhang, Runjiao ; He, Xianli ; Shi, Caiyu ; Zhao, Jing ; Zhao, Xin ; Ren, Tingting ; Wu, Dan ; Xing, Jinliang ; An, Jiaze ; Lan, Xianchun ; Huang, Qichao ; Yan, Zeyu

To prevent cell death induced by elevated oxidative stress, cancer cells activate a series of antioxidant defense mechanisms to mitigate cytotoxicity, thereby enhancing the resistance to pro-oxidative therapy. However, the underlying antioxidant mechanisms in cancer cells remain inadequately understood. Through co-immunoprecipitation followed by quantitative mass spectrometry analysis, we for the first time identified that cytoplasmic ALDH1L1 translocates into mitochondria and co-localizes with mitochondrial transcription factor TFAM in cancer cells in a ROS-dependent feedback manner. Mitochondria-translocated ALDH1L1 maintains mitochondrial redox homeostasis by producing NADPH. Moreover, our findings revealed that the ROS-mediated oxidative modification of ALDH1L1 is necessary for its interaction with HSP90β and subsequent translocation into mitochondria via TOM70, where it binds to TFAM to prevent degradation by LONP1. Furthermore, we found that mitochondrial ALDH1L1 antagonized the double-edged role of ROS in cancer cell survival, indicating that disruption of ALDH1L1 expression promoted cancer cell proliferation and autophagy but concurrently diminished cellular capacity to counteract ROS-induced apoptosis. Consistently, ALDH1L1 knockout enhanced the anti-tumor effect of low-dose pro-oxidant Elesclomol, thereby achieving better efficacy and safety of pro-oxidant therapy. Furthermore, our results demonstrated that the combination of Elesclomol with HSP90 inhibitor Ganetespib exhibited synergistic anti-tumor effects. In conclusion, our findings that mitochondria-translocated ALDH1L1 functions as a feedback regulator of redox homeostasis in cancer cells to enhance the resistance to pro-oxidative therapy can provide critical insights into developing effective pro-oxidative therapies against tumors.

01 Mar 2026·Advanced Science

Alkaline Phosphatase‐Activated NIR‐II AIEgens Nanosystem for Surgical and Postoperative Closed‐Loop Therapy of Advanced Osteosarcoma

Article

Author: Sun, Wei ; Zan, Pengfei ; Mu, Haoran ; Zhang, Li ; Hu, Qian ; Han, Jing ; Zuo, Dongqing ; Li, Ruotong ; Lu, Hengli ; Tao, Yining ; Yang, Binhui ; Liu, Kaiyuan ; Wang, Hongsheng ; Zhu, Xingjun ; Shen, Jiakang

ABSTRACT:

In advanced osteosarcoma, tumor invasion often prevents complete resection, and immunotherapy is limited by the tumor's immunosuppressive nature, making residual lesions a key source of recurrence. To address this, we developed an ALP‐responsive theranostic nanoplatform (SGPF) integrating an AIEgens (STEA) and HSP90 inhibitor (Ganetespib) for imaging‐guided resection and multimodal therapy. Selenium‐doped STEA enables NIR‐IIb imaging and enhanced phototherapy via narrowed HOMO‐LUMO gaps and nonradiative decay optimization. At tumor sites, ALP‐triggered nanomicelle cleavage releases STEA and Ganetespib while vaporizing perfluorohexane to relieve hypoxia. NIR irradiation induces pyroptosis via caspase‐3/GSDME activation and immunogenic cell death, while Ganetespib suppresses glycolysis (HK2/PKM2 downregulation) to reverse lactate‐driven immunosuppression. This dual‐action strategy synergistically enhances T‐cell infiltration and ablates residual/metastatic lesions, offering a transformative approach for unresectable Osteosarcoma.

01 Feb 2026·INTERNATIONAL IMMUNOPHARMACOLOGY

Corrigendum to “Ganetespib as an inhibitor of heat shock protein 90 alleviates pulmonary fibrosis by inhibiting the Wnt/β-catenin signaling pathway” [Int. Immunopharmacol. 168 (2026) 115837]

Author: Song, Shuai ; Zhou, Meng ; Xu, Jingjing ; Wang, Zhe ; Qin, Yunkun ; Wang, Na ; Qin, Xiangyi ; Zhou, Fang

News (Medical) associated with Ganetespib

16 May 2024

·www.biospace.com

Angle PLC Announces Study of Ovarian Cancer CTCs Using Parsortix

INDEPENDENT STUDY OF OVARIAN CANCER CTCS HARVESTED BY THE PARSORTIX SYSTEM HIGHLIGHTS POTENTIAL TO PREDICT PROGRESSION FREE SURVIVAL FOR DRUG TRIALS The study investigated 123 metastatic ovarian cancer patients over two and a half years using the Parsortix system to assess 474 longitudinal patient samples Downstream qPCR molecular analysis of the Parsortix harvest for ESR1 and ERCC1 genes may be an early predictor of progression free survival and cancer progression respectively GUILDFORD, SURREY / ACCESSWIRE / May 16, 2024 / ANGLE plc ("the Company") (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is delighted to announce the publication of a study using the Parsortix® system to identify markers present in CTCs harvested from metastatic mutant-p53 platinum-resistant ovarian cancer (PROC) patients. The study was conducted as an offshoot of the European multi-centre GANNET53 Phase II clinical trial (NCT02012192) funded by the EU 7th Framework Programme (Grant agreement ID: 602602). The study investigated the efficacy of ganetespib in combination with paclitaxel vs. paclitaxel alone. Patients were enrolled across 12 clinical centres in Germany, Belgium, France, and Austria. The translational study, which the research team believes is the largest study of CTCs in ovarian cancer (in terms of number of patient samples analysed), was conducted by researchers at the Medical University of Vienna, Austria. The study analysed a total of 474 blood samples collected from 123 PROC patients at baseline (i.e. prior to first administration of study drugs), and at multiple timepoints over a period of two and a half years during treatment until disease progression. A panel of 27 gene transcripts (RNA) was analysed on Parsortix-harvested CTCs using standard laboratory qPCR analysis. The authors identified two CTC-associated markers with potential prognostic value. ERCC1, a key gene of the DNA damage response pathway, was associated with an increased risk of disease progression and worse outcomes, whereas the presence of ESR1, a gene encoding oestrogen receptor alpha (ERα), was associated with a reduced progression risk. The presence of ESR1 transcripts together with concurrent absence of ERCC1 transcripts in CTC-enriched samples at baseline and during treatment cycles was found to be predictive of improved progression free survival (PFS). Whereas the presence of ERCCI transcripts and the absence of ESR1 transcripts at baseline and during treatment cycles indicated a 12.77× greater likelihood (odds ratio) of cancer progression. The analysis of these biomarkers has the potential to provide an early indication of PFS ahead of clinical trial results and suggests that CTC characterisation may be a valuable tool for pharma drug trials in the future. In addition, the authors conclude that molecular characterisation of CTCs before and during treatment has the potential to be a useful tool to monitor ovarian cancer patients and may provide further insights into the biology of this difficult to treat disease. According to clinicaltrials.gov there are 1,024 active interventional studies enrolling more than 825,000 participants in ovarian cancer. The study is published as a peer-reviewed journal article in the International Journal of Cancer and is available online at ANGLE Chief Scientific Officer, Karen Miller, commented: "We are pleased to share this peer-reviewed publication by the Medical University of Vienna and the European GANNET53 consortium. The paper demonstrates the potential utility of molecular characterisation of CTCs enriched using the Parsortix system in monitoring ovarian cancer patients throughout their treatment and during follow-up. The scale of this study, both in terms of numbers of patients and timescale of follow-up, is particularly important. It clearly demonstrates how use of the Parsortix system in cancer trials could in the future enable our pharma customers to gain an early understanding of how patients are responding to their drug." Ovarian cancer accounted for over 320,000 new cases of cancer, and over 200,000 deaths worldwide in 20221. Diagnosis often occurs at a later stage, and although patients often respond well to initial treatment with a platinum-based chemotherapy, many patients relapse and develop resistance to treatment2. 1. American Cancer Society. Global Cancer Facts & Figures 5th Edition. Atlanta: American Cancer Society; 2024 2. Zamwar UM, Anjankar AP. Aetiology, epidemiology, histopathology, classification, detailed evaluation, and treatment of ovarian cancer. Cureus. 2022; 14:e30561 ANGLE plc +44 (0) 1483 343434 Andrew Newland, Chief Executive Ian Griffiths, Finance Director Berenberg (NOMAD and Broker) Toby Flaux, Ciaran Walsh, Milo Bonser +44 (0) 20 3207 7800 FTI Consulting Simon Conway, Ciara Martin Matthew Ventimiglia (US) +44 (0) 203 727 1000 +1 (212) 850 5624 For Research Use Only. Not for use in diagnostic procedures. For Frequently Used Terms, please see the Company's website on Notes for editors About ANGLE plc ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected circulating tumour cell (CTC) harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis. ANGLE's commercial businesses are focusing on diagnostic products and clinical services. Diagnostic products include the Parsortix® system, associated consumables and assays. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma. Over 90 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit . SOURCE: ANGLE plc View the original press release on accesswire.com

Phase 2Clinical Result

21 Sep 2023

·synapse.patsnap.com

Analysis on the Research Progress of HSP90 inhibitors

Heat shock protein 90 (HSP90) is an ATP-dependent molecular chaperone essential in eukaryotic organisms. It is ubiquitously present in both prokaryotic and eukaryotic cells, excluding archaea, and is one of the core members of the heat shock protein family. In normal cells, HSP90 makes up 1-2% of the total proteins, this percentage increasing to 4-6% under stressful conditions. Moreover, HSP90 is highly conserved evolutionarily, with its function being consistent across cells of different species origins. Molecular chaperone proteins in cells play a critical role in protein folding through their binding with substrate proteins. HSP90 is such a molecular chaperone protein, capable of high activation in the harsh tumour environment of various solid tumours, yet remains relatively dormant in normal tissues. Therefore, it is considered a potential target for tumour drug development. In addition, HSP90 serves as a downstream modulator for the signaling of Tumor Necrosis Factor-alpha (TNF-α) and Interleukin-17A (IL-17A). HSP90 Competitive LandscapeAccording to the data provided by Patsnap Synapse-Global Drug Intelligence Database: the following figure shows that as of 18 Sep 2023, there are a total of 55 HSP90 drugs worldwide, from 67 organizations, covering 78 indications, and conducting 224 clinical trials. 👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs , indications, organizations, clinical trials, clinical results, and drug patents related to this target. The analysis of the target HSP90 reveals a competitive landscape with companies like Wakamoto Pharmaceutical Co., Ltd., D. Western Therapeutics Institute, Inc., and Samus Therapeutics LLC leading the way in R&D efforts. The indications with approved drugs include Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Glaucoma. Small molecule drugs, including small molecule-drug conjugates, are progressing rapidly, indicating the primary focus of R&D efforts. The European Union, the United Kingdom, and Japan are the fastest-developing regions, with emerging markets in China and South Korea. Overall, the target HSP90 shows promising potential for the development of innovative drugs in various indications, with a strong focus on small molecule drugs. HSP90 inhibitors entering Phase III clinical trials: GanetespibGanetespib is a small molecule drug that falls under the category of biomedicine. It specifically targets HSP90, a protein that plays a crucial role in the folding and stabilization of other proteins. By inhibiting HSP90, Ganetespib aims to disrupt the function of various proteins involved in disease processes. The therapeutic areas in which Ganetespib is being explored include neoplasms (abnormal growth of cells), endocrinology and metabolic diseases, urogenital diseases, and hemic and lymphatic diseases. These broad therapeutic areas suggest that Ganetespib has the potential to be effective in treating a wide range of conditions. 👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug. Currently, Ganetespib is being investigated for its efficacy in treating several specific indications. These include myelodysplastic syndromes (a group of disorders characterized by abnormal blood cell production), acute myeloid leukemia (a type of cancer that affects the blood and bone marrow), mesothelioma (a rare cancer that affects the lining of the lungs, abdomen, or heart), and ovarian cancer. The drug is developed by Synta, Inc., an originator organization in the pharmaceutical industry. Synta, Inc. is responsible for the discovery and development of Ganetespib, and they hold the rights to the drug. In terms of its development stage, Ganetespib has reached Phase 3 of clinical trials. This indicates that the drug has already undergone extensive testing in preclinical and early clinical stages and has shown promising results. Phase 3 trials involve a larger number of participants and aim to further evaluate the drug's safety and effectiveness compared to existing treatments or a placebo. In summary, Ganetespib is a small molecule drug that targets HSP90 and is being investigated for its potential in treating various neoplasms, endocrinology and metabolic diseases, urogenital diseases, and hemic and lymphatic diseases. It is currently in Phase 3 clinical trials and is being developed by Synta, Inc. LuminespibLuminespib is a small molecule drug that falls under the category of biomedicine. It specifically targets HSP90, a protein involved in various cellular processes. The drug is primarily developed for the treatment of neoplasms, which are abnormal growths of tissue commonly referred to as tumors. Luminespib has shown potential in treating specific types of neoplasms, including head and neck neoplasms, adenocarcinoma of the lung, and squamous cell carcinoma. These indications suggest that the drug may be effective in combating various forms of cancer. 👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug. The drug's originator organization is Ligand UK Ltd., a pharmaceutical company involved in the research and development of innovative therapies. This suggests that Luminespib is a product of extensive scientific research and development efforts. In terms of its development stage, Luminespib has reached Phase 2, which is considered a significant milestone in the drug development process. Phase 2 trials involve testing the drug on a larger group of patients to evaluate its safety and efficacy. The fact that Luminespib has reached this stage indicates that it has shown promising results in earlier stages of development. It is worth noting that Luminespib has reached Phase 2 in both global and Chinese markets. This suggests that the drug has gained recognition and interest not only internationally but also within the Chinese pharmaceutical industry. In terms of regulation, Luminespib is classified under the Special Review Project. This classification implies that the drug may have unique characteristics or potential benefits that warrant special attention from regulatory authorities. In summary, Luminespib is a small molecule drug developed by Ligand UK Ltd. It targets HSP90 and shows potential in treating various neoplasms, including head and neck neoplasms, adenocarcinoma of the lung, and squamous cell carcinoma. The drug has reached Phase 2 in both global and Chinese markets, indicating promising results in earlier stages of development. Luminespib falls under the Special Review Project category, suggesting unique characteristics or potential benefits that require special regulatory attention.

10 Mar 2021

·www.biospace.com

Aldeyra Therapeutics to Present at the OIS Dry Eye Innovation Showcase on March 11, 2021

March 10, 2021 13:00 UTC LEXINGTON, Mass.--(BUSINESS WIRE)-- Aldeyra Therapeutics Inc. (Nasdaq: ALDX) (Aldeyra) today announced that President and Chief Executive Officer Todd C. Brady, M.D., Ph.D. will discuss the potential of reproxalap as a novel, rapid-onset first-line treatment for dry eye disease as part of the Ophthalmology Innovation Summit’s Dry Eye Disease Innovation Showcase, which will take place virtually on Thursday, March 11, 2021 from 1:00 p.m. to 4:00 p.m. ET. The event will include a market overview and company presentations as well as panel discussions featuring experts who will provide industry and clinical perspectives on the dry eye disease market. Registration is complimentary. To register, click here: About Aldeyra Therapeutics, Inc. Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead investigational compounds, reproxalap and ADX-629, target RASP (reactive aldehyde species), which are elevated in ocular and systemic inflammatory disease and result in cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in development for COVID-19 and ovarian cancer. For more information, visit and follow us on LinkedIn, Facebook, and Twitter.

100 Deals associated with Ganetespib

External Link

KEGG	Wiki	ATC	Drug Bank
D10126	-	-	DB12047

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Myelodysplastic Syndromes	Phase 3	United Kingdom	-	07 Jul 2014
Acute Myeloid Leukemia	Phase 3	Denmark	-	01 Jul 2014
Advanced Lung Non-Small Cell Carcinoma	Phase 3	United States	Synta Pharmaceuticals Corp.	01 Apr 2013
Advanced Lung Non-Small Cell Carcinoma	Phase 3	Austria	Synta Pharmaceuticals Corp.	01 Apr 2013
Advanced Lung Non-Small Cell Carcinoma	Phase 3	Belgium	Synta Pharmaceuticals Corp.	01 Apr 2013
Advanced Lung Non-Small Cell Carcinoma	Phase 3	Bosnia and Herzegovina	Synta Pharmaceuticals Corp.	01 Apr 2013
Advanced Lung Non-Small Cell Carcinoma	Phase 3	Canada	Synta Pharmaceuticals Corp.	01 Apr 2013
Advanced Lung Non-Small Cell Carcinoma	Phase 3	Croatia	Synta Pharmaceuticals Corp.	01 Apr 2013
Advanced Lung Non-Small Cell Carcinoma	Phase 3	Czechia	Synta Pharmaceuticals Corp.	01 Apr 2013
Advanced Lung Non-Small Cell Carcinoma	Phase 3	France	Synta Pharmaceuticals Corp.	01 Apr 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01042379 (I-SPY2, SABCS2025)	Phase 2	HER2-negative breast cancer Neoadjuvant HER2-negative \| immune genes low \| no DNA repair deficiency	440	Neoadjuvant ganetespib (HER2-/Immune-/DRD-)	bzqytkqcqw(yybktlogyr) = mvyvfspakk wyzamlngzz (jsdvsgcrva ) View more	Positive	11 Dec 2025
				Standard neoadjuvant chemotherapy control (paclitaxel-AC) (HER2-/Immune-/DRD-)	bzqytkqcqw(yybktlogyr) = bblvpdhgeb wyzamlngzz (jsdvsgcrva ) View more
NCT03783949 (EUDARIO, CTgov)	Phase 2	Primary peritoneal carcinoma \| Platinum-Sensitive Ovarian Carcinoma \| Fallopian Tube Carcinoma	122	Carboplatin+Gemcitabine+Paclitaxel+niraparib	gtkzyaaayj(fuzzaaulpx) = cinxupvxtk bugyxchxow (htoqjodwnp, tylwfixfaj - bsirkjaehq) View more	-	11 Jun 2025
NCT01042379 (I-SPY2, Pubmed)	Phase 2	Breast Cancer Neoadjuvant	233	Ganetespib	skrutsblhl(qzmtprmpso) = isrjjppykn ipvgaoybwv (xdxhtiduom )	-	01 Dec 2022
				Standard NAC control	skrutsblhl(qzmtprmpso) = tzuqlhgekz ipvgaoybwv (xdxhtiduom )
NCT01042379 (I-SPY2, ASCO2022) Manual	Phase 2	Triple Negative Breast Cancer Neoadjuvant HER2 Negative \| ER Negative \| PR Negative	363	pembrolizumab (Immune+ TNBC)	tstchjligt(pgotibahiv) = ocfdwzyour zjyjcdpbex (bjkjtqgxqq )	Positive	02 Jun 2022
				carboplatin (VC) (Immune+ TNBC)	tstchjligt(pgotibahiv) = cttybisvfr zjyjcdpbex (bjkjtqgxqq )
NCT01167114 (Pubmed \| Invest New Drugs) Manual	Phase 2	Neoplasms Second line	26	Ganetespib	kopxiowrxh(tkvirfjejs) = eajvuumica xdyuvqtaoa (prjwmqbtji ) View more	Negative	01 Oct 2020
NCT01590160 (MESO-02, Pubmed \| Clin Cancer Res) Manual	Phase 1	Malignant Pleural Mesothelioma	27	pemetrexed+cisplatin+carboplatin+Ganetespib	csuudqgcnc(ngouwvbykv) = ztcrcrjroi vvwinkkogo (fdseilmsvs ) View more	Positive	15 Sep 2020
NCT02008877 (SARC023, Pubmed) Manual	Phase 1/2	Sarcoma \| Neurofibrosarcoma	20	Sirolimus+Ganetespib (phase 1 ：refractory sarcoma)	nfyzkdxazr(klypqrtagf) = emhzwrlncp pxudqrhnst (wnlnvkjkbe )	Negative	30 Jan 2020
				Sirolimus+Ganetespib (phase 2 ： MPNST)	nfyzkdxazr(klypqrtagf) = depsdcstet pxudqrhnst (wnlnvkjkbe )
NCT02012192 (GANNET53, Pubmed) Manual	Phase 1/2	Ovarian Epithelial Carcinoma	10	Paclitaxel+Ganetespib (cohort 1)	hdiwwqikvn(gwzfxbxglc) = sexghpcdvz rmovtbzmfp (fdihugkexv )	Positive	10 Sep 2019
				Paclitaxel+Ganetespib (cohorts 2 and 3)	hdiwwqikvn(gwzfxbxglc) = txqdbsfxin rmovtbzmfp (fdihugkexv )
NCT02012192 (GANNET53, CTgov)	Phase 1/2	Primary Peritoneal High-Grade Serous Adenocarcinoma \| Platinum-Resistant Primary Peritoneal Carcinoma \| Ovarian Epithelial Carcinoma ... View more	133	Ganetespib+Paclitaxel (Ganetespib + Paclitaxel)	kjlnpgcepf(lfwmegfyxl) = yxpnedlmij nvxohawcqc (vvhnifqvyz, eplxqmvsjh - yzgyqvdbnv) View more	-	13 Aug 2019
				Paclitaxel (Paclitaxel)	kjlnpgcepf(lfwmegfyxl) = pgpwbdtact nvxohawcqc (vvhnifqvyz, kmsltaadgg - nsnwdwmsle) View more
NCT02008877 (SARC023, CTgov)	Phase 1/2	Neurofibrosarcoma	20	ganetespib+Sirolimus	kvwbaxmsjj = ypxmeiowuh jtldxkzooh (rjvukttkco, smfeszwcyd - przwztiksw) View more	-	02 May 2019

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis